Conservatives unveil new product safety regime

Kondro, Wayne
May 2008
CMAJ: Canadian Medical Association Journal;5/6/2008, Vol. 178 Issue 10, p1268
Academic Journal
The article reports on a new omnibus consumer protection legislation introduced by the minority federal Conservative government in Canada. It relates that the new legislation highlights progressive licensing for pharmaceuticals and biologics, as well as the mandatory reporting of adverse drug reactions by hospitals and other prescribed health care institutions. The legislation also requires drug manufacturers to disclose adverse drug reactions to regulatory authorities. It is also noted that the government will also extends its authority to recall unsafe products, to include any therapeutic, cosmetic or consumer product deemed to present serious risk to health.


Related Articles

  • Directives, Directives, Directives. Marwaha, Gurminder // Pharmaceutical Technology Europe;Jun2005, Vol. 17 Issue 6, p4 

    The article presents information about the pharmaceutical industry. More often one comes across at meetings, exhibitions and conferences is the number of directives and legislations that the pharmaceutical industry needs to adhere to. The feeling is that, although there is an obvious need for...

  • A New Food and Drugs Act. ANDERSON, FLOYD // America;1/27/1934, Vol. 50 Issue 17, p395 

    The article reports on the pending bill in the U.S. Congress in January 1934 that would amend the 1906 Food and Drugs Act. It explores the defects of the 1906 Act, the abuses of drug manufacturers and the changes that will be incorporated in the bill. The author presents information on the...

  • Hatch-Waxman Act II: biologics legislation.  // Drug Store News;10/9/2006, Vol. 28 Issue 13, p20 

    The article reports on the plan of U.S. Representative Henry Waxman to introduce a legislation that would establish a clear pathway for the approval of generic biologic products also known as bionergics or biosimilars. The said bill will give benefit to all uninsured American patients that are...

  • States move to comply with drug pedigree laws. Celia, Frank // Drug Topics;6/6/2005, Vol. 149 Issue 11, p52 

    This article discusses the prescription drug pedigree laws that three states in the U.S. are trying to implement to counter the rise in drug counterfeiting. Three states now have prescription drug pedigree laws on their books, another 15 have similar legislation in the pipeline, and the U.S....

  • Cough syrup laws could mean big OTC headache. Johnsen, Michael // Drug Store News;6/25/2007, Vol. 29 Issue 8, p82 

    The article reports on the legislation that could put some restrictions on the selling of Dextromethorphan (DXM) in drug stores in the U.S. Most drug store retailers are voluntarily restricting sales of DXM to minors with an ID prompt at the checkout registers whenever any DXM product is...

  • Drug Product Selection: The Florida Experience. Vuturo, George J.; Krischer, Jeffrey P.; McCormick, William C. // American Journal of Public Health;May80, Vol. 70 Issue 5, p479 

    Abstract: Drug product selection, the act of selecting and dispensing a lower cost generically equivalent product to that prescribed, is made possible in 46 states through recently enacted legislation. Florida's legislation is unique in that it requires pharmacists to product select under...

  • New laws could alter U.S. import rules.  // World Trade;Apr2008, Vol. 21 Issue 4, p12 

    The article reports that the Canadian pharmaceutical industry is worried that the next U.S. president will pass the Dorgan-Snowe bill. It is raising concerns about an outflow of medicine that could threaten drug supply in Canada. Under the pending bill, U.S. wholesalers, pharmacies and...

  • EC "fails to distinguish between information and advertising" Watson, Rory // BMJ: British Medical Journal (International Edition);4/12/2008, Vol. 336 Issue 7648, p792 

    The article reports on criticism which the European Commission has received from medical and consumer organizations in response to its plans to develop legislation which would allow pharmaceutical companies to use the television, radio and print media to provide information on prescription drugs...

  • PDUFA. Kracov, Daniel // Pharmaceutical Executive;Sep2007, Vol. 27 Issue 9, p62 

    The article offers a guide to Prescription Drug User Fee Act (PDUFA IV), which is pending in U.S. Congress. It focuses on the details on the many provisions the two bills, the Senate Food and Drug Administration (FDA) Act and the House FDA Amendments Act, have in common, as well as the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics